Stanford Hospital and Clinics

Summary

Stanford Hospital and Clinics is a medical facility located in Stanford, California. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lymphoma, Lung Cancer and other specialties. Stanford Hospital and Clinics is involved with conducting 179 clinical trials across 429 conditions. There are 21 research doctors associated with this hospital, such as Andrei Iagaru, MD, David P. Lee, MD, Seema Nagpal, MD, and Kristen Ganjoo, M.D..

Top PIs

Clinical Trials running at Stanford Hospital and Clinics

Breast Cancer

Lung Cancer

Cardiovascular Disease

Parkinson's disease

Diabetes

Chronic Kidney Disease

Solid Tumors

Parathyroid Adenomas

Abdominal Aortic Aneurysm

Cancer

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.

Recruiting

2 awards

Phase 3

3 criteria

Sacituzumab Govitecan + Pembrolizumab

for Triple Negative Breast Cancer

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Recruiting

2 awards

Phase 3

6 criteria

T-DM1 vs TH

for Breast Cancer

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel

Recruiting

1 award

Phase 2